Money Talks: Why weight-loss drugs will resha...

An ousted former opposition leader started a new party—called the New Party. We assess its chances at the ballot box, and under President Recep Tayyip Erdogan’s thumb. A surrogacy scandal in Germany has prompted a government reshuffle, with Chancellor Friedrich Merz left holding ...  Show more

Wildfires in France and Spain are only growing worse by the day. We examine what can be done as a future of more fires, and worse ones, becomes more assured. A dig into data on women at work shows several indicators starting to move in the wrong direction. And the American cities ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ...  Show more